期刊
ONCOTARGET
卷 8, 期 13, 页码 22218-22234出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.14731
关键词
triple negative breast cancer; breast cancer; kinases; novel therapies
资金
- Instituto de Salud Carlos III, ACEPAIN [PI16/0112]
- Diputacion de Albacete and CRIS Cancer Foundation
- BAE (Bcca Ampliacion de Estudios)
- Ministry of Economy and Competitiveness of Spain [BFU2015-71371-R]
- Instituto de Salud Carlos III through the Spanish Cancer Centers Network Program [RD12/0036/0003]
- CIBERONC
- scientific foundation of the AECC
- CRIS Foundation
- European Community through the regional development funding program (FEDER)
Triple negative breast cancer (TNBC) is still an incurable disease despite the great scientific effort performed during the last years. The huge heterogeneity of this disease has motivated the evaluation of a great number of therapies against different molecular alterations. In this article, we review the biological bases of this entity and how the known molecular evidence supports the current preclinical and clinical development of new therapies. Special attention will be given to ongoing clinical studies and potential options for future drug combinations.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据